Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysfunction in unresectable pancreatic cancer.
Anti-reflux metal stent
Covered metal stent
Distal malignant biliary obstruction
Pancreatic cancer
Recurrent biliary obstruction
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
31
05
2022
accepted:
16
12
2022
medline:
5
5
2023
pubmed:
30
12
2022
entrez:
29
12
2022
Statut:
ppublish
Résumé
The use of duckbill-type anti-reflux metal stents (DMS) in reinterventions after covered metal stent (CMS) dysfunction has been reported in patients with distal malignant biliary obstruction (MBO). However, the superiority of DMS over conventional CMS (c-CMS) has not been established. Therefore, we conducted this retrospective study to evaluate the long-term efficacy and safety of DMS as a second stent in comparison with c-CMS. We investigated consecutive patients with distal MBO due to unresectable pancreatic cancer who underwent reintervention after dysfunction of initial biliary CMS at our institution. We compared causes of recurrent biliary obstruction (RBO), time to RBO (TRBO), adverse events (AEs), and reintervention rates of DMS and c-CMS in this stenting. A total of 76 patients were included (DMS 41 and c-CMS 35). While overall RBO rates were similar between the two groups (46% vs. 63%, p = 0.172), RBO due to non-occlusion cholangitis tended to be less frequent in the DMS group than in the c-CMS group (2% vs. 14%, p = 0.089). Median TRBO was significantly longer in the DMS group (286 days vs. 112 days, p = 0.029). DMS was identified as the only significant risk factor for TRBO (hazard ratio, 0.52; p = 0.044). Overall AE rates were significantly lower in the DMS group (2% vs. 23%, p = 0.010), with non-occlusion cholangitis being the most common AE in the c-CMS group. Endoscopic reintervention was successfully performed in all patients in both groups, despite failed stent removal in 15% of patients in DMS group. DMS was associated with a significantly longer TRBO and lower rate of AEs compared with c-CMS in reinterventions after initial CMS dysfunction. DMS may be preferable to c-CMS as a second stent after biliary CMS dysfunction.
Sections du résumé
BACKGROUND
The use of duckbill-type anti-reflux metal stents (DMS) in reinterventions after covered metal stent (CMS) dysfunction has been reported in patients with distal malignant biliary obstruction (MBO). However, the superiority of DMS over conventional CMS (c-CMS) has not been established. Therefore, we conducted this retrospective study to evaluate the long-term efficacy and safety of DMS as a second stent in comparison with c-CMS.
METHODS
We investigated consecutive patients with distal MBO due to unresectable pancreatic cancer who underwent reintervention after dysfunction of initial biliary CMS at our institution. We compared causes of recurrent biliary obstruction (RBO), time to RBO (TRBO), adverse events (AEs), and reintervention rates of DMS and c-CMS in this stenting.
RESULTS
A total of 76 patients were included (DMS 41 and c-CMS 35). While overall RBO rates were similar between the two groups (46% vs. 63%, p = 0.172), RBO due to non-occlusion cholangitis tended to be less frequent in the DMS group than in the c-CMS group (2% vs. 14%, p = 0.089). Median TRBO was significantly longer in the DMS group (286 days vs. 112 days, p = 0.029). DMS was identified as the only significant risk factor for TRBO (hazard ratio, 0.52; p = 0.044). Overall AE rates were significantly lower in the DMS group (2% vs. 23%, p = 0.010), with non-occlusion cholangitis being the most common AE in the c-CMS group. Endoscopic reintervention was successfully performed in all patients in both groups, despite failed stent removal in 15% of patients in DMS group.
CONCLUSIONS
DMS was associated with a significantly longer TRBO and lower rate of AEs compared with c-CMS in reinterventions after initial CMS dysfunction. DMS may be preferable to c-CMS as a second stent after biliary CMS dysfunction.
Identifiants
pubmed: 36581786
doi: 10.1007/s00464-022-09836-0
pii: 10.1007/s00464-022-09836-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3498-3506Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Almadi MA, Barkun A, Martel M (2017) Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction: a series of meta-analyses. Am J Gastroenterol 112:260–273
doi: 10.1038/ajg.2016.512
pubmed: 27845340
Isayama H, Yasuda I, Ryozawa S, Maguchi H, Igarashi Y, Matsuyama Y, Katanuma A, Hasebe O, Irisawa A, Itoi T, Mukai H, Arisaka Y, Okushima K, Uno K, Kida M, Tamada K (2011) Results of a Japanese multicenter, randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-test): covered wallstent versus doublelayer stent. Dig Endosc 23:310–315
doi: 10.1111/j.1443-1661.2011.01124.x
pubmed: 21951091
Nakai Y, Isayama H, Wang HP, Rerknimitr R, Khor C, Yasuda I, Kogure H, Moon JH, Lau J, Lakhtakia S, Ratanachu-Ek T, Seo DW, Lee DK, Makmun D, Dy F, Liao WC, Draganov PV, Almadi M, Irisawa A, Katanuma A, Kitano M, Ryozawa S, Fujisawa T, Wallace MB, Itoi T, Devereaux B (2020) International consensus statements for endoscopic management of distal biliary stricture. J Gastroenterol Hepatol 35:967–979
doi: 10.1111/jgh.14955
pubmed: 31802537
pmcid: 7318125
Tringali A, Hassan C, Rota M, Rossi M, Mutignani M, Aabakken L (2018) Covered vs. uncovered self-expandable metal stents for malignant distal biliary strictures: a systematic review and meta-analysis. Endoscopy 50:631–641
doi: 10.1055/s-0043-125062
pubmed: 29342491
Hamada T, Isayama H, Nakai Y, Togawa O, Kogure H, Kawakubo K, Tsujino T, Sasahira N, Hirano K, Yamamoto N, Arizumi T, Ito Y, Matsubara S, Sasaki T, Yagioka H, Yashima Y, Mohri D, Miyabayashi K, Mizuno S, Nagano R, Takahara N, Toda N, Tada M, Omata M, Koike K (2011) Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Gastrointest Endosc 74:548–555
doi: 10.1016/j.gie.2011.04.046
pubmed: 21794859
Hamada T, Nakai Y, Isayama H, Sasaki T, Kogure H, Kawakubo K, Sasahira N, Yamamoto N, Togawa O, Mizuno S, Ito Y, Hirano K, Toda N, Tada M, Koike K (2013) Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: an analysis using a time-dependent covariate. Surg Endosc 27:1243–1248
doi: 10.1007/s00464-012-2585-9
pubmed: 23073685
Togawa O, Isayama H, Tsujino T, Nakai Y, Kogure H, Hamada T, Sasaki T, Yashima Y, Yagioka H, Arizumi T, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Toda N, Tada M, Koike K (2013) Management of dysfunctional covered self-expandable metallic stents in patients with malignant distal biliary obstruction. J Gastroenterol 48:1300–1307
doi: 10.1007/s00535-013-0751-z
pubmed: 23354625
Ornellas LC, Stefanidis G, Chuttani R, Gelrud A, Kelleher TB, Pleskow DK (2009) Covered Wallstents for palliation of malignant biliary obstruction: primary stent placement versus reintervention. Gastrointest Endosc 70:676–683
doi: 10.1016/j.gie.2009.02.012
pubmed: 19560137
Misra SP, Dwivedi M (2009) Reflux of duodenal contents and cholangitis in patients undergoing self-expanding metal stent placement. Gastrointest Endosc 70:317–321
doi: 10.1016/j.gie.2008.12.054
pubmed: 19539920
Hu B, Wang TT, Shi ZM, Wang SZ, Lu R, Pan YM, Huang H, Wang SP (2011) A novel antireflux metal stent for the palliation of biliary malignancies: a pilot feasibility study (with video). Gastrointest Endosc 73:143–148
doi: 10.1016/j.gie.2010.08.048
pubmed: 20970788
Lee KJ, Chung MJ, Park JY, Lee DH, Jung S, Bang BW, Park SW, Chung JB, Song SY, Bang S (2013) Clinical advantages of a metal stent with an S-shaped anti-reflux valve in malignant biliary obstruction. Dig Endosc 25:308–312
doi: 10.1111/j.1443-1661.2012.01382.x
pubmed: 23369050
Kim DU, Kwon CI, Kang DH, Ko KH, Hong SP (2013) New antireflux self-expandable metal stent for malignant lower biliary obstruction: in vitro and in vivo preliminary study. Dig Endosc 25:60–66
doi: 10.1111/j.1443-1661.2012.01324.x
pubmed: 23286258
Hu B, Wang TT, Wu J, Shi ZM, Gao DJ, Pan YM (2014) Antireflux stents to reduce the risk of cholangitis in patients with malignant biliary strictures: a randomized trial. Endoscopy 46:120–126
doi: 10.1055/s-0034-1364872
pubmed: 24477367
Lee YN, Moon JH, Choi HJ, Choi MH, Lee TH, Cha SW, Cho YD, Choi SY, Lee HK, Park SH (2016) Effectiveness of a newly designed antireflux valve metal stent to reduce duodenobiliary reflux in patients with unresectable distal malignant biliary obstruction: a randomized, controlled pilot study (with videos). Gastrointest Endosc 83:404–412
doi: 10.1016/j.gie.2015.08.084
pubmed: 26385187
Hamada T, Isayama H, Nakai Y, Iwashita T, Ito Y, Mukai T, Yagioka H, Saito T, Togawa O, Ryozawa S, Hirano K, Mizuno S, Yamamoto N, Kogure H, Yasuda I, Koike K (2019) Antireflux covered metal stent for nonresectable distal malignant biliary obstruction: multicenter randomized controlled trial. Dig Endosc 31:566–574
doi: 10.1111/den.13381
pubmed: 30803046
Kin T, Ishii K, Okabe Y, Itoi T, Katanuma A (2020) Feasibility of biliary stenting to distal malignant biliary obstruction using a novel designed metal stent with duckbill-shaped anti-reflux valve. Dig Endosc. https://doi.org/10.1111/den.13827
doi: 10.1111/den.13827
pubmed: 33026695
Renno A, Abdel-Aziz Y, Ahmed T, Alastal Y, Toseef J, Al-Abboodi Y, Nawras A (2019) Antireflux valve metal stent versus conventional self-expandable metal stent in distal malignant biliary obstruction: a systematic review and meta-analysis. Ann Gastroenterol 32:605–613
pubmed: 31700238
pmcid: 6826073
Yamada Y, Sasaki T, Takeda T, Mie T, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Igarashi Y, Sasahira N (2021) A novel laser-cut fully covered metal stent with anti-reflux valve in patients with malignant distal biliary obstruction refractory to conventional covered metal stent. J Hepatobiliary Pancreat Sci 28:563–571
doi: 10.1002/jhbp.966
pubmed: 33835728
Isayama H, Hamada T, Yasuda I, Itoi T, Ryozawa S, Nakai Y, Kogure H, Koike K (2015) TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 27:259–264
doi: 10.1111/den.12379
pubmed: 25209944
Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ (2010) A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 71:446–454
doi: 10.1016/j.gie.2009.10.027
pubmed: 20189503
Japanese Gastric Cancer Association (1998) Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 1:10–24
Dutz A, Löck S (2019) Competing risks in survival data analysis. Radiother Oncol 130:185–189
doi: 10.1016/j.radonc.2018.09.007
pubmed: 30314718
Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(1141–1154):1114
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl 48:452–458
doi: 10.1038/bmt.2012.244
Kida M, Miyazawa S, Iwai T, Ikeda H, Takezawa M, Kikuchi H, Watanabe M, Imaizumi H, Koizumi W (2011) Endoscopic management of malignant biliary obstruction by means of covered metallic stents: primary stent placement vs. re-intervention. Endoscopy 43:1039–1044
doi: 10.1055/s-0030-1256769
pubmed: 21971926
Nakai Y, Isayama H, Kogure H, Hamada T, Togawa O, Ito Y, Matsubara S, Arizumi T, Yagioka H, Mizuno S, Sasaki T, Yamamoto N, Hirano K, Tada M, Koike K (2014) Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. J Gastroenterol Hepatol 29:1744–1749
doi: 10.1111/jgh.12602
pubmed: 24720610
Kwon CI, Moon JP, Yun H, Jeong S, Koh DH, Lee WJ, Ko KH, Kang DH (2018) Evaluation of valve function in antireflux biliary metal stents. BMC Gastroenterol 18:150
doi: 10.1186/s12876-018-0878-8
pubmed: 30340463
pmcid: 6194677
Mandai K, Nakamura S, Uno K, Yasuda K (2021) Successful re-intervention through stent mesh after novel antireflux covered metal biliary stent placement. Endoscopy 53:E94-e95
doi: 10.1055/a-1201-3045
pubmed: 32659807